Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
Generation Bio (Nasdaq: GBIO) announced its participation in the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio (Nasdaq: GBIO) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2023, at 4:30 p.m. PST in San Francisco, CA. The company focuses on innovative genetic medicines targeting rare and prevalent diseases. A live webcast of the presentation will be available on the investor section of their website. Generation Bio's platform features unique technologies designed to enable durable, redosable treatments with large genetic payloads for specific cell types.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was +26.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10th at 4:30 p.m. PST in San Francisco, CA.
A live webcast of the company presentation will be available on the investor section of the company website at investors.generationbio.com.
About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.